Vertex Pharmaceuticals Incorpor

Valuation Analysis

About the Company

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment

Vertex Pharmaceuticals Incorpor Stock at a Glance

Vertex Pharmaceuticals Incorpor (VRTX) is currently trading at $444.93 with a market capitalization of $112.9B. The trailing P/E ratio stands at 26.39x, with a forward P/E of 20.72x. The 52-week range spans from $362.50 to $507.92; the current price is 12.4% below the yearly high. Year-over-year revenue growth stands at +7.8%. The net profit margin stands at 35.51%.

💰 Dividend

Vertex Pharmaceuticals Incorpor currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

29 analysts rate Vertex Pharmaceuticals Incorpor (VRTX) on consensus: Buy. The average price target is $548.69, implying +23.32% from the current price. Analyst price targets range from $330.00 to $641.00.

Vertex Pharmaceuticals Incorpor: The Investment Case in Detail

Vertex Pharmaceuticals Incorpor (VRTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 61.4% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 54.39% gross margin and 38.13% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 35.51%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

What to Watch Next

• The forward P/E of 20.72x is meaningfully below the trailing 26.39x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 23.32% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Vertex Pharmaceuticals Incorpor?

Compare top-rated brokers — low fees, trusted providers, fully regulated.